Review article: the future of microbiome-based therapeutics

被引：63

作者：

Gulliver, Emily L. ^{[1
,2
]}

Young, Remy B. ^{[1
,2
]}

Chonwerawong, Michelle ^{[1
,2
]}

D'Adamo, Gemma L. ^{[1
,2
]}

Thomason, Tamblyn ^{[1
,2
]}

Widdop, James T. ^{[1
,2
]}

Rutten, Emily L. ^{[1
,2
]}

Rossetto Marcelino, Vanessa ^{[1
,2
]}

Bryant, Robert V. ^{[3
,4
]}

Costello, Samuel P. ^{[3
,4
]}

O'Brien, Claire L. ^{[5
,6
]}

Hold, Georgina L. ^{[7
]}

Giles, Edward M. ^{[1
,2
,8
]}

Forster, Samuel C. ^{[1
,2
]}

机构：

[1] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia

[2] Monash Univ, Dept Mol & Translat Sci, Clayton, Vic, Australia

[3] Queen Elizabeth Hosp, Dept Gastroenterol, Woodville, SA, Australia

[4] Univ Adelaide, Sch Med, Adelaide, SA, Australia

[5] Australian Natl Univ, Med Sch, Canberra, ACT, Australia

[6] Canberra Hosp, Gastroenterol & Hepatol Unit, Canberra, ACT, Australia

[7] Univ New South Wales, St George & Sutherland Clin Sch, Microbiome Res Ctr, Sydney, NSW, Australia

[8] Monash Univ, Dept Paediat, Clayton, Vic, Australia

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2022年 / 56卷 / 02期

基金：

澳大利亚研究理事会;

关键词：

CLOSTRIDIUM-DIFFICILE INFECTION; EXCLUSIVE ENTERAL NUTRITION; CHAIN FATTY-ACIDS; INFLAMMATORY-BOWEL-DISEASE; ACTIVE ULCERATIVE-COLITIS; HUMAN GUT MICROBIOME; FECAL MICROBIOTA; DOUBLE-BLIND; CROHNS-DISEASE; DIETARY FIBER;

D O I：

10.1111/apt.17049

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background From consumption of fermented foods and probiotics to emerging applications of faecal microbiota transplantation, the health benefit of manipulating the human microbiota has been exploited for millennia. Despite this history, recent technological advances are unlocking the capacity for targeted microbial manipulation as a novel therapeutic. Aim This review summarises the current developments in microbiome-based medicines and provides insight into the next steps required for therapeutic development. Methods Here we review current and emerging approaches and assess the capabilities and weaknesses of these technologies to provide safe and effective clinical interventions. Key literature was identified through Pubmed searches with the following key words, 'microbiome', 'microbiome biomarkers', 'probiotics', 'prebiotics', 'synbiotics', 'faecal microbiota transplant', 'live biotherapeutics', 'microbiome mimetics' and 'postbiotics'. Results Improved understanding of the human microbiome and recent technological advances provide an opportunity to develop a new generation of therapies. These therapies will range from dietary interventions, prebiotic supplementations, single probiotic bacterial strains, human donor-derived faecal microbiota transplants, rationally selected combinations of bacterial strains as live biotherapeutics, and the beneficial products or effects produced by bacterial strains, termed microbiome mimetics. Conclusions Although methods to identify and refine these therapeutics are continually advancing, the rapid emergence of these new approaches necessitates accepted technological and ethical frameworks for measurement, testing, laboratory practices and clinical translation.

引用

页码：192 / 208

页数：17

共 225 条

[1]

Abu-Sbeih H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0714-x

[2]

Aguilar C, 2021, EXP MOL MED, V53, P1471

[3] Postbiotics: An evolving term within the functional foods field [J].